Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (172)	12/9/2003 1:41:26 PM
From: Thai Chung	Respond to of 946

Dow Jones Business News Cell Therapeutics Reports Positive Data From Trisenox Study Tuesday December 9, 1:36 pm ET SAN DIEGO (Dow Jones)--A trial showed a combination treatment using the leukemia drug Trisenox, marketed by Cell Therapeutics Inc. (NasdaqNM:CTIC - News) , improved the conditions of patients suffering from relapsed or chemotherapy-resistant myeloma, a tumor of the bone marrow. ADVERTISEMENT In particular, the combination regimen of Trisenox, low-dose chemotherapy and vitamin C improved the kidney function in patients with severe kidney damage from myeloma, Cell Therapeutics said in a press release Tuesday. The biopharmaceutical company, which focuses on oncology products, said the studies will be used to back an ongoing phase II study of the regimen. Of the study's 10 heavily pretreated patients, six showed no disease progression from five to 15 months following treatment, the company said. Reported side effects include fatigue, marrow suppression, accumulation of fluid in tissue, stomach ailments and headaches. A spokesperson wasn't immediately available for comment. The Food and Drug Administration approved Trisenox in 2000 for treating relapsed or treatment-resistant acute promyelocytic leukemia, a rare and life- threatening form of blood cancer. Shares of Cell Therapeutics recently traded at $8.40, up 33 cents, or 4.1%. Company Web site: cticseattle.com -Jerry Abejo; Dow Jones Newswires; 201-938-5400 Email this story - Set a News Alert

To: Icebrg who wrote (172)	12/17/2003 11:50:55 AM
From: Icebrg	Read Replies (1) \| Respond to of 946

Treatment Protocol With Arsenic and Retinoic Acid Highly Effective for APL Charlene Laino Dec. 15, 2003 (San Diego) — A combination of all-trans retinoic acid (ATRA) and arsenic trioxide is more effective than either alone for treating patients with acute promyelocytic leukemia (APL), results of a new study suggest. The findings were presented here at the American Society of Hematology 45th Annual Meeting. "While both agents have previously been shown to be effective in inducing clinical remissions in APL patients, our study shows the combination works even better," said Sai-Juan Chen, MD, an oncologist at the Shanghai Institute of Hematology in China. Dr. Chen and a multicenter team randomized 61 newly diagnosed APL patients to remission induction and maintenance therapy with ATRA, arsenic, or a combination of the two. All three groups also received doxorubicin, cytarabine, and homoharrington, administered sequentially followed by ATRA maintenance. Chemotherapy was initiated if the peripheral white blood count was over 30 to 40 109 cells/L. At a median follow-up of 15 months, all 20 patients in the combination therapy group remained in complete remission compared with only 30 of 37 patients treated with monotherapy (P < .05), Dr. Chen reported. Relapses occurred in 20% of patients in the ATRA arm and in 10% of those in the arsenic trioxide group, Dr. Chen said. Also, the time to achieve a complete response was significantly lower in the combination treatment arm compared with either of the monotherapy arms (P < .001 and .01 for the ATRA and arsenic group, respectively). One patient in the ATRA group died of treatment-related complications; otherwise adverse effects were about the same in all three groups. Ronald Hoffman, MD, president of the American Society of Hematology and the Eileen Hiedrick Professor of Oncology and director of the Cancer Center at the University of Illinois College of Medicine in Chicago, told Medscape that the combination protocol could become the standard of care for patients with APL. "Until now, we could expect over 90% of patients with APL to achieve a complete response, with 75% still disease-free at 2 years," he said. "With combination chemotherapy with all trans-retinoic acid and arsenic, we are able to improve on these rates." According to Dr. Chen, the synergistic effect of ATRA and arsenic on apoptosis and degradation of PML-RAR alpha oncoprotein might explain why the combination therapy is better than treatment with either agent alone. ASH 45th Annual Meeting: Abstract 486. Presented Dec. 8, 2003 Reviewed by Gary D. Vogin, MD medscape.com